Polygeline: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 1, 2026🚩 Report this page

Polygeline

Active ingredient

Sold as HAEMACCEL

GB MHRA

Drug class: -
Availability: See label
Markets covered: 1
Products on record: 1

Overview

Polygeline is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	May 1, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised May 1, 2026[1]

1. As a plasma volume substitute in the initial treatment of hypovolaemic shock due to: a) Haemorrhage (visible or concealed) b) Burns, peritonitis, pancreatitis, crush injuries 2. Fluid replacement in plasma exchange 3. Extra-corporeal circulation 4.
Isolated organ perfusion 5. As a carrier solution for insulin

How to take

Sources & citations

[1]MHRA (UK) · PL370710022 · revised May 1, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 1, 2026[1]

During or after the infusion of volume-expanding solutions, transient urticarial skin reactions (wheals), hypotension, tachycardia, bradycardia, nausea/vomiting, dyspnoea, increases in temperature and/or shivering may occasionally occur.
Rare cases of severe hypersensitivity reactions including shock have been observed. Treatment will depend on the nature and severity of the reaction. Mild reactions: administer corticosteroids and antihistamines. v. c. injection) should immediately be given.
Administration of adrenalin should be repeated every 15 minutes until improvement occurs. Circulatory collapse requires volume replacement, preferably monitored by a central venous pressure line. Large volumes of electrolyte solution may be necessary because, in severe anaphylactic shock, plasma loss may constitute up to 40 % of the plasma volume.
v. injection of an H1 antagonist such as 10 - 20 mg chlorpheniramine may be given. Histamine release has been shown to be a cause of anaphylactic side-effects associated with infusions of Haemaccel. g. anaesthetics, muscle relaxants, analgesics, ganglia blockers and anticholinergic drugs).
Due to the calcium content of Haemaccel, the serum calcium concentrations may be found to be slightly elevated for a temporary period especially when large amounts of Haemaccel are administered by rapid infusion. So far, no reports have been received of cases involving clinical signs of hypercalcaemia resulting from an infusion of Haemaccel.
The infusion of Haemaccel may result in a temporary increase in the erythrocyte sedimentation rate. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 1, 2026[1]

In the following cases, Haemaccel is indicated to a restricted extent only; if the physician considers the infusion necessary, it should be given taking special precautions. g. increased stroke volume, elevated blood pressure), or an increase in interstitial fluid volume, or haemodilution could represent a special risk for the patient.
Examples of such conditions are: congestive heart failure, hypertension, oesophageal varices, pulmonary oedema, haemorrhagic diathesis, renal and post-renal anuria. g. allergic persons and patients with a history of histamine response; also patients who in the previous 7 days have received a drug which releases histamine).
In the latter cases, Haemaccelmay be given only after taking appropriate prophylactic steps. Reactions caused by histamine release can be avoided by the prophylactic use of H1 and H2 receptor antagonists. Inappropriate rapid administration of Haemaccel, especially to normovolaemic patients may cause the release of vasoactive substances.
The exact mechanism of this histamine release has not been clearly defined. 20g potassium chloride per 500ml. 1847mmol sodium in each 500ml vial. This should be taken into consideration by patients on a controlled sodium diet. 005mmol potassium in each 500ml vial.
This should be taken into consideration by patients on a controlled potassium diet.

This is not medical advice. Consult a qualified healthcare professional.